Cargando…
Metabolic flux-driven sialylation alters internalization, recycling, and drug sensitivity of the epidermal growth factor receptor (EGFR) in SW1990 pancreatic cancer cells
In prior work we reported that advanced stage, drug-resistant pancreatic cancer cells (the SW1990 line) can be sensitized to the EGFR-targeting tyrosine kinase inhibitors (TKIs) erlotinib and gefitinib by treatment with 1,3,4-O-Bu(3)ManNAc (Bioorg. Med. Chem. Lett. (2015) 25(6):1223-7). Here we prov...
Autores principales: | Mathew, Mohit P., Tan, Elaine, Saeui, Christopher T., Bovonratwet, Patawut, Sklar, Samuel, Bhattacharya, Rahul, Yarema, Kevin J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341816/ https://www.ncbi.nlm.nih.gov/pubmed/27613843 http://dx.doi.org/10.18632/oncotarget.11582 |
Ejemplares similares
-
Metabolic Glycoengineering Sensitizes Drug-Resistant Pancreatic Cancer Cells to Tyrosine Kinase Inhibitors Erlotinib and Gefitinib
por: Mathew, Mohit P., et al.
Publicado: (2015) -
Identification of sialylated glycoproteins from metabolically oligosaccharide engineered pancreatic cells
por: Tian, Yuan, et al.
Publicado: (2015) -
Development of a novel method to evaluate sialylation of glycoproteins and analysis of gp96 sialylation in Hela, SW1990 and A549 cell lines
por: Liang, Yangui, et al.
Publicado: (2015) -
Cell Line-, Protein-, and Sialoglycosite-Specific Control of Flux-Based Sialylation in Human Breast Cells: Implications for Cancer Progression
por: Saeui, Christopher T., et al.
Publicado: (2020) -
Cell Surface and Membrane Engineering: Emerging Technologies and Applications
por: Saeui, Christopher T., et al.
Publicado: (2015)